MZMarina V. Zhukina

Marina V. Zhukina

*This is an algorithmically generated author record based on publicly available information.

Marina V. Zhukina has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Irina I. Amiantova

    Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова», Москва, Российская Федерация

    3 shared publications
  • L. N. Pritvorova

    Federal State Budgetary Scientific Institution «I. Mechnikov Research Institute for Vaccines and Sera», Moscow, Russian Federation

    3 shared publications
  • Lyubov N. Nesterenko

    I. Mechnikov Research Institute of Vaccines and Sera

    3 shared publications
  • Vera V. Dotsenko

    Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова», Москва, Российская Федерация

    3 shared publications
  • Vera Yu. Kabargina

    Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова», Москва, Российская Федерация

    3 shared publications
  • Vitaliy Vasilievich Zverev

    I.I. Mechnikov Institute of Vaccines and Sera, 105064 Moscow, Russia

    3 shared publications

Latest Publications

  • Разработка иммуноферментной тест-системы для количественного определения IgG-антител к вирусу гепатита Е в сыворотке крови человека и оценка ее диагностической эффективности

    by Л.н. Притворова, Г.и. Алаторцева, Л.н. Нестеренко, В.в. Доценко, И.и. Амиантова, В.ю. Кабаргина, М.в. Жукина, З.ш. Нурматов, У.с. Каратаева, Р.о. Касымова, et al.

    Введение. Для выявления антител к вирусу гепатита Е (ВГЕ) наиболее предпочтительным является метод иммуноферментного анализа (ИФА) с количественной оценкой результатов. Данный подход, основанный на строгих критериях, обеспечивает прецизионное определение концентрации антител, что позволяет проводить достоверную диагностику и эпидемиологический мониторинг. Цель исследования. Разработка тест-системы для определения концентрации IgG-антител к ВГЕ в сыворотке крови человека методом непрямого ИФА и оценка ее диагностической эффективности. Материалы и методы. Наборы реагентов «ДС-ИФА-АНТИ-HEV-G» (ООО «НПО Диагностические системы», Россия) и recomWeel HEV IgG (Euroimmun, Германия). Международный стандартный образец ВОЗ Anti-Hepatitis E Serum, Human code: 95/584 (NIBSC, Англия). Иммунореагенты, полученные в ФГБНУ НИИВС им. И.И. Мечникова: рекомбинантный антиген ORF2/3-ВГЕ1/3, моноклональные антитела к IgG человека («Сорбент», Россия), конъюгированные с пероксидазой хрена, специфические поликлональные антитела кролика к белку ORF2/3-ВГЕ1/3, конъюгированные с IgG человека. Сыворотки крови здоровых людей и лиц, инфицированных вирусами гепатитов А, В, С, Е, ВИЧ и герпесвирусами. Результаты и обсуждение. Разработана иммуноферментная тест-система «Скрин-ВГЕ-IgG» для определения концентрации IgG к вирусу гепатита Е (МЕ/мл) в сыворотке крови человека в непрямом формате. Синтезирован и стандартизирован по международному ВОЗ-стандарту Anti-Hepatitis E Serum, Human, NIBSC code: 95/584, искусственный калибратор для определения концентрации АТ-ВГЕ. Определены основные функциональные характеристики «Скрин-ВГЕ-IgG» в соответст- вии с требованиями ГОСТ 51352-2013. Тест-система апробирована на образцах сывороток крови больных гепатитом Е (n = 75) и условно здоровых лиц (n = 320). По данным ROC-анализа, диагностическая чувствительность тест-системы составляет 98,7 %, диагностическая спе- цифичность — 99,9 %. Показано отсутствие перекрестной реактивности «Скрин-ВГЕ-IgG» на образцах с серологическими маркерами других вирусных гепатитов и патологии печени иной этиологии (n = 83). Сравнительные испытания тест-системы «Скрин-ВГЕ-IgG» и ее коммерческого аналога – набора реагентов recomWeel HEV IgG, — показали более высокую диагностическую чувствительность разработан- ной тест-системы. Заключение. Разработанная тест-система обладает высокими показателями диагностической эффективности и может быть рекомендована к применению в клинической практике для определения концентрации IgG-антител к ВГЕ. Introduction. To detect antibodies to the hepatitis E virus (HEV), the enzyme-linked immunosorbent assay (ELISA) is the preferred method with a quantitative assessment of results. This method, based on strict criteria, al- lows for the precise determination of the quantity of antibodies, enabling reliable diagnosis and epidemiological monitoring. The aim. To develop a test system for measuring the concentration of IgG antibodies against HEV in human serum using indirect ELISA, and to evaluate its diagnostic accuracy. Materials and methods. Reagents kits «DS-ELISA-ANTI-HEV-G» (Diagnostic Systems, Russia) and «recomWeel HEV IgG» (Euroimmun, Germany) were used, as well as WHO International Standard Samples of Anti- Hepatitis E Serum (NIBSC, England) and immunoreagents from the «I.I. Mechnikov Research Institute of Vaccines and Sera»: recombinant antigen ORF2/3-HEV1/3, monoclonal antibodies to human IgG conjugated with horseradish peroxidase (Sorbent, Russia), and specific polyclonal rabbit antibodies for the protein ORF2/3-HEVI/3 conjugated with human IgG. Blood serum samples from healthy individuals and those infected with hepatitis A, B, C, E, HIV and herpes viruses. Results and discussion. It has been developed of enzyme immunoassay kit reagents called «Screen-HEV-IgG» to determine the concentration of hepatitis E virus IgG (AT-HEV) in human blood serum. The kit uses an indirect ELISA method to measure the concentration of AT-HEV in IU/ml. An artificial calibrator has been synthesized and standardized based on the World Health Organization's...

  • Open Access

    Hepatitis A virus seroprevalence in Kyrgyzstan

    by Galina I. Alatortseva, Lyudmila N. Pritvorova, Zuridin Sh. Nurmatov, Lyubov N. Nesterenko, Vera V. Dotsenko, Vera Yu. Kabargina, Irina I. Amiantova, Marina V. Zhukina, Zamira O. Abdrakhmanova, Uulkan S. Karatayeva, et al.

    Introduction. Kyrgyzstan, among other Central Asian countries, is one of the highly endemic regions for hepatitis A. An important tool for assessing the true burden of these infections on the population and the success of ongoing prevention programs is to study the prevalence of markers of past and current hepatitis A in all age groups of the population, as well as the intensity of population immunity to this virus in regions with different morbidity. Aim. To study the hepatitis A virus (HAV) seroprevalence among residents of the Kyrgyzstan regions. Materials and methods. Blood serum samples from conditionally healthy individuals (n = 2297) who sought medical attention at medical institutions in Bishkek, Batken, Chüy, Jalal-Abad, Issyk-Kul, Osh, Talas and Naryn regions. IgM and IgG antibodies to hepatitis A virus (anti-HAV IgM, anti-HAV IgG) were determined using the «Vectohep A-IgM» and «Vectohep A-IgG» (Vector-Best) enzyme immunoassay kits. Statistical processing of the results was carried out using Excel and Medcalc programs. Results. 80.3% of the studied samples contained HAV serologic markers, of which 80.3% contained anti-HAV IgG antibodies and 4.7% contained anti-HAV IgM antibodies. All IgM-positive samples contained specific IgG antibodies. Such samples were identified with the same frequency among women and men. The highest seropositivity rates were observed in the age groups 30–39, 40–49, and 50–59 years. The number of individuals with anti-HAV IgG antibodies in their blood serum increased with their age. An analysis of the immunostructure of the examined individuals by the level of anti-HAV IgG in serum showed relatively stable ratios of low, medium and high levels of antibodies in groups older than 30 years. The most frequently anti-HAV IgM and IgG antibodies were detected in samples from residents of Bishkek. Anti-HAV IgG antibodies were detected in samples from all surveyed regions of Kyrgyzstan, while anti-HAV IgM antibodies were identified in samples from Chüy, Issyk-Kul and Osh regions, as well as Bishkek. Conclusion. Hepatitis A remains widespread in Kyrgyzstan. The determination of HAV seromarkers in the algorithms of complex hepatitis diagnostics and seroepidemiological studies remains relevant. A decrease in the level of population immunity to HAV in younger age group indicates the country's transition from high to medium endemicity, which suggests an increase in the number of clinically pronounced cases in the future in the absence of a hepatitis A vaccination program for children.

  • Open Access

    Line immunoassay for detection of IgG antibodies to hepatitis E virus (Hepeviridae, Orthohepevirus, Orthohepevirus A)

    by G. I. Alatortseva, V. V. Dotsenko, L. N. Nesterenko, L. N. Luhverchik, V. Yu. Kabargina, I. I. Amiantova, M. V. Zhukina, S. V. Zhavoronok, Z. S. Nurmatov, A. Z. Nurmatov, et al.

    Introduction. The diagnostic efficacy of methods for hepatitis E serodiagnostic varies over a wide range; therefore, the combined use of tests of various formats is recommended. The aim of the research was to develop a test system for the detection of IgG antibodies to hepatitis E virus (HEV) in human serum by linear immunoassay (LIA). Material and methods. Serum samples from patients with hepatitis and healthy individuals were tested using commercial enzyme-linked immunosorbent assay systems for the presence of IgG antibodies to viral agents causing hepatitis and other infections associated with liver pathology. Recombinant antigens ORF2 and ORF3 of HEV genotypes 1 and 3 were used. The “RecomLine HEV IgG/IgM” reagent kit (Mikrogen GmbH, Germany) was used as a comparison test system. Results. The first Russian diagnostic kit “Blot-HEV”, designed to detect IgG antibodies to individual HEV proteins in human serum using LIA, was developed. The antigenic base is represented by strips of a nitrocellulose membrane with immobilized recombinant antigens ORF2 (aa 406–660) and ORF3 (aa 1–113) of HEV genotypes 1 and 3, and control antigens in the form of discrete lines. The conjugate was mouse monoclonal antibodies to human class G immunoglobulins labeled with horseradish peroxidase. The chromogen solution contained the 3,3’,5,5’-tetramethylbenzidine. A visual and digital recording of results was provided. The analytical sensitivity of the test kit was 0.625 IU/ml for ORF2 antigens and 2.5 IU/ml for ORF3 antigens. The absence of the influence of endogenous interfering substances on the results of the analysis and the absence of cross-reactions with antibodies to hepatitis pathogens of the other etiologies had been shown. The sensitivity of the test system compared to the “RecomLine HEV IgG/IgM” kit was 92%, specificity 97%. Shelf life in condition of storage was determined to be 12 months. Conclusions. The developed test can be used to confirm the results of ELISA in laboratory diagnosis of hepatitis E.